Synthetic pentadecapeptide
UnapprovedBPC-157: what the FDA has actually decided
BPC-157 is not approved by the FDA for human use, and that has not changed. In April 2026 it was removed from the Category 2 list of bulk substances that may present significant safety risks, and in July 2026 an FDA advisory committee voted 8 to 6 to recommend it for the 503A Bulks List. Neither step makes it legal to prescribe or sell today. The committee vote is non-binding and the FDA must still complete formal rulemaking.
Where this stands
Every headline reading "FDA clears BPC-157" is wrong. Sequence of fact: added to Category 2 in September 2023; removed from Category 2 on April 23, 2026 after the nominations were withdrawn, which is not the same as approval; recommended for the 503A Bulks List by the Pharmacy Compounding Advisory Committee on July 23, 2026 by 8 votes to 6. The FDA must now accept the recommendation, publish a notice of proposed rulemaking, run notice and comment, and issue a final rule. Realistic timeline is eight to twelve months at minimum, into 2027.
We do not link to sellers of unapproved compounds, we do not name vendors, and we publish no dosing for them.
Key facts
- Approval status
- Unapproved new drug
- Advisory committee vote
- 8 to 6 in favor, July 23, 2026. Non-binding
- Prohibited in sport
- Yes, at all times
Sources
Every claim above is checked against the primary text, and the date is the day we last opened it.
-
1
July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee
U.S. Food and Drug Administration Primary text read and checked Checked August 23, 2026
-
2
BPC-157: A Prohibited Peptide and an Unapproved Drug Found in Health and Wellness Products
Operation Supplement Safety, U.S. Department of Defense Primary text read and checked Checked August 23, 2026
-
3
BPC-157: Experimental Peptide Creates Risk for Athletes
USADA Primary text read and checked Checked August 23, 2026